Pancreatic ductal adenocarcinoma epidemiology and risk assessment: Could we prevent? Possibility for an early diagnosis

Bekkali, Noor; Oppong, Kofi

doi:10.4103/eus.eus_60_17

Cited by 15 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDAC is an exocrine tumor that occurs in the pancreatic ducts. The well-known risk factors for PDAC development include alcohol and tobacco use, ethnicity, type 2 diabetes, obesity, blood groups, microbiome composition, infections, and inherited germline mutations ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies

et al. 2023

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is characterized by a high mortality rate and poor prognosis. Current treatments for PDAC, are ineffective due to a prominent immunosuppressive PDAC tumor microenvironment (TME). Although B lymphocytes are highly infiltrated into PDAC, the importance of B lymphocytes in tumorigenesis is largely neglected. B cells play a dual role in the PDAC tumor microenvironment, acting as either anti-tumorigenic or pro-tumorigenic depending on where they are localized. Tumor-infiltrating B cells, which reside in ectopic lymph nodes, namely tertiary lymphoid structures (TLS), produce anti-tumor antibodies and present tumor antigens to T cells to contribute to cancer immunosurveillance. Alternatively, regulatory B cells (Bregs), dispersed inside the TME, contribute to the dampening of anti-tumor immune responses by secreting anti-inflammatory cytokines (IL-10 and IL-35), which promote tumor growth and metastasis. Determining the role of Bregs in the PDAC microenvironment is thus becoming increasingly attractive for developing novel immunotherapeutic approaches. In this minireview, we shed light on the emerging role of B cells in PDAC development and progression, with an emphasis on regulatory B cells (Bregs). Furthermore, we discussed the potential link of Bregs to immunotherapies in PDAC. These current findings will help us in understanding the full potential of B cells in immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In the process, we were able to identify a key link between AGING miR-34a, SERPINE1, and PDAC. Just as the age is a risk factor for the development of PDAC [70], PAI-1 is a part of the senescence-associated secretory phenotype (SASP) [71] and its expression is accordingly elevated in the elderly [72,73]. Future studies are aimed at delineating the interactions between miR-34a and SERPINE1 in the context of PDAC and aging.…”

Section: Discussionmentioning

confidence: 99%

TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer

Akula

Ruvolo

McCubrey

2020

Aging

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a disease of aging. The TP53 gene product regulates cell growth, aging, and cancer. To determine the important targets of TP53 in PDAC, we examined the expression of 440 proteins on a reverse phase protein array (RPPA) in PDAC-derived MIA-PaCa-2 cells which either had WT-TP53 or lacked WT-TP53. MIA-PaCa-2 cells have a TP53 mutation as well as mutant KRAS and represent a good in vitro model to study PDAC. RPPA analysis demonstrated expression of tumor promoting proteins in cells that lacked WT-TP53; and this feature could be reversed significantly when the cells were transfected with vector encoding WT-TP53 or treated with berberine or a modified berberine (BBR). Expression of miR-34a-associated signaling was elevated in cells expressing WT-TP53 compared to cells expressing mTP53. Results from in vivo studies using human PDAC specimens confirmed the in vitro results as the expression of miR-34a and associated signaling was significantly decreased in PDAC specimens compared to non-cancerous tissues. This study determined SERPINE1 as a miR-34a target with relevance to the biology of PDAC. Thus, we have identified a key target (SERPINE1) of the TP53/miR-34a axis that may serve as a potential biomarker for early detection of pancreatic cancer.

show abstract

“…Only 10% of PDAC cases appear related to family history. Inherited cancer syndromes with known germline mutations, such as the Lynch syndrome (MLH1, MLH2, MLH6, PMS2), familiar breast and ovarian cancer (BRCA1 and BRCA2), familial adenomatous polyposis (FAP), familial atypical multiple mole melanoma (CDKN2A), and Peutz–Jeghers (STK11/LKB1), show an increased risk of PDAC [ 8 ].…”

Section: Pancreatic Ductal Adenocarcinoma (Pdac)mentioning

confidence: 99%

The Dual Role of Necroptosis in Pancreatic Ductal Adenocarcinoma

Giansante,

Stati,

Sancilio

et al. 2023

IJMS

View full text Add to dashboard Cite

Pancreatic cancer (PC) is the seventh leading cause of cancer-related death. PC incidence has continued to increase by about 1% each year in both men and women. Although the 5-year relative survival rate of PC has increased from 3% to 12%, it is still the lowest among cancers. Hence, novel therapeutic strategies are urgently needed. Challenges in PC-targeted therapeutic strategies stem from the high PC heterogeneity and from the poorly understood interplay between cancer cells and the surrounding microenvironment. Signaling pathways that drive PC cell growth have been the subject of intense scrutiny and interest has been attracted by necroptosis, a distinct type of programmed cell death. In this review, we provide a historical background on necroptosis and a detailed analysis of the ongoing debate on the role of necroptosis in PC malignant progression.

show abstract

Pancreatic ductal adenocarcinoma epidemiology and risk assessment: Could we prevent? Possibility for an early diagnosis

Cited by 15 publications

References 19 publications

Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies

Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies

TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer

The Dual Role of Necroptosis in Pancreatic Ductal Adenocarcinoma

Contact Info

Product

Resources

About